Ligand Pharmaceuticals Terminates TR-Beta Program License with Viking Therapeutics Amidst Dispute

summarizeSummary

Ligand Pharmaceuticals terminated its TR-Beta Program license agreement with Viking Therapeutics, citing a material breach, but Viking is disputing the termination.

check_boxKey Events

• Termination of TR-Beta Program License

  Ligand Pharmaceuticals delivered notice to Viking Therapeutics, Inc. to terminate the TR-Beta Program under their Master License Agreement, effective May 4, 2026.

• Assertion of Material Breach

  Ligand's termination is based on its assertion that Viking materially breached its obligation to use 'Commercially Reasonable Efforts' to develop and commercialize the program.

• Regaining of Program Rights

  Upon termination, all licenses granted to Viking for the TR-Beta Program will cease, and Viking is obligated to grant Ligand a non-exclusive, royalty-bearing license for related intellectual property.

• Ongoing Dispute with Viking

  Viking is disputing Ligand's right to terminate the TR-Beta Program, and Ligand intends to vigorously enforce its position.

auto_awesomeAnalysis

Ligand Pharmaceuticals has terminated its Master License Agreement for the TR-Beta Program, including key assets VK2809 and VK0214, with Viking Therapeutics. Ligand asserts that Viking materially breached its obligation to use commercially reasonable efforts in developing and commercializing the program. This action allows Ligand to regain all licenses and obtain a royalty-bearing license from Viking for any related intellectual property. However, Viking is disputing Ligand's right to terminate, introducing potential legal uncertainty. This move reflects Ligand's active portfolio management, following its recent $739 million acquisition of XOMA Royalty Corporation, and could be an effort to re-evaluate or take direct control of underperforming assets.